Skip to main content
Top
Published in: Pathology & Oncology Research 1/2019

01-01-2019 | Letter to the Editor

Cerebrovascular Complications and Polycythaemia Vera

Authors: Imelda Marton, Éva Pósfai, Angéla Csomor, László Vécsei, Zita Borbényi, Katalin Sas

Published in: Pathology & Oncology Research | Issue 1/2019

Login to get access

Excerpt

Polycythaemia vera (PV) is a stem cell-derived myeloid haematologic malignancy. It is characterized by an expansion of one or more haematopoietic cell lineages, resulting in increased mature blood components in the peripheral blood. The disease features include erythrocytosis, leukocytosis and/or thrombocytosis, as a consequence of which PV may exhibit a unique prothrombic state [1, 2]. There is a possibility of progression into acute myeloid leukaemia or myelofibrosis, the 10-year risk ranging between 3% and 10%, but the life expectancy of patients with PV is commonly affected by thrombo-haemorrhagic events, with a reported incidence of 12–39% [1, 3]. The clinical manifestations of the thrombotic events in PV patients may vary from mild microvascular circulatory disturbances (e.g. erythromelalgia, tinnitus or vertigo) to more severe complications, such as migraine-like cerebral transient ischaemic attacks, transient ischaemic attacks, ischaemic stroke, myocardial infarction or venous thrombosis (e.g. cerebral sinus and venous thrombosis or deep venous thrombosis). Information relating to the association of PV and cerebrovascular complications such as stroke and transient ischaemic attacks from detailed clinical aspects are limited in the relevant literature [47]. …
Literature
2.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
5.
go back to reference Sanahuja J, Marti-Fabregas J, Marti-Vilalta JL (2005) Carotid thrombus and cerebral infarction as the initial clinical manifestation of polycythemia vera. Neurologia 20(4):194–196PubMed Sanahuja J, Marti-Fabregas J, Marti-Vilalta JL (2005) Carotid thrombus and cerebral infarction as the initial clinical manifestation of polycythemia vera. Neurologia 20(4):194–196PubMed
6.
go back to reference Arboix A, Besses C (1997) Cerebrovascular disease as the initial clinical presentation of haematological disorders. Eur Neurol 37(4):207–211CrossRefPubMed Arboix A, Besses C (1997) Cerebrovascular disease as the initial clinical presentation of haematological disorders. Eur Neurol 37(4):207–211CrossRefPubMed
10.
go back to reference Vokó Z, Széles G, Kardos L, Németh R, Ádány R (2008) The epidemiology of cerebrovascular diseases in Hungary after the millennium. LAM ( Lege Artis Medicinae) 18(1):31–38 Vokó Z, Széles G, Kardos L, Németh R, Ádány R (2008) The epidemiology of cerebrovascular diseases in Hungary after the millennium. LAM ( Lege Artis Medicinae) 18(1):31–38
12.
go back to reference Santisakultarm TP, Paduano CQ, Stokol T, Southard TL, Nishimura N, Skoda RC, Olbricht WL, Schafer AI, Silver RT, Schaffer CB (2014) Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. https://doi.org/10.1111/jth.1273 Santisakultarm TP, Paduano CQ, Stokol T, Southard TL, Nishimura N, Skoda RC, Olbricht WL, Schafer AI, Silver RT, Schaffer CB (2014) Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. https://​doi.​org/​10.​1111/​jth.​1273
Metadata
Title
Cerebrovascular Complications and Polycythaemia Vera
Authors
Imelda Marton
Éva Pósfai
Angéla Csomor
László Vécsei
Zita Borbényi
Katalin Sas
Publication date
01-01-2019
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-017-0329-9

Other articles of this Issue 1/2019

Pathology & Oncology Research 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine